Novo Nordisk to target Global Blood Therapeutics ($1.4bn)

Novo Nordisk is reportedly in talks to acquire US-based Global Blood Therapeutics Inc, a biotech company focused on developing therapies targeting blood diseases. Global Blood Therapeutics shares rose more than 32% (NASDAQ) on the news, taking the group’s market capitalization to $1.4bn. Novo Nordisk already has a product portfolio for blood diseases, focused on hemophilia, whose mainstay is NovoSeven. (Source: Reuters)